New Hope for PPMS: Roche’s Oral Therapy Fenebrutinib Matches Gold Standard in Landmark Trial

SAN DIEGO — In what researchers are hailing as the most significant development for primary progressive multiple sclerosis (PPMS) in nearly a decade, pharmaceutical giant Roche announced Saturday that its investigational oral drug, fenebrutinib, successfully met its primary goals in a late-stage Phase III clinical trial.

The data, presented as a late-breaking session at the ACTRIMS Forum 2026, reveals that fenebrutinib is non-inferior to the current gold-standard infusion, Ocrevus (ocrelizumab), in slowing disability progression. If approved, fenebrutinib would become the first-ever oral treatment capable of penetrating the brain to treat this particularly aggressive form of the disease.

A New Frontier in MS Treatment

Multiple sclerosis (MS) affects more than 2.9 million people globally. While treatments for the relapsing-remitting form of the disease have flourished, those with Primary Progressive MS (PPMS)—roughly 15% of the MS population—have had far fewer options.

Unlike other forms of MS, PPMS is characterized by a steady decline in neurological function from the very beginning, without the periods of recovery or “remission” typical of the disease. This decline is driven by “smoldering” inflammation within the central nervous system (CNS) that traditional drugs often struggle to reach.

Fenebrutinib belongs to a new class of drugs known as Bruton’s tyrosine kinase (BTK) inhibitors. Unlike existing therapies that primarily target B cells in the bloodstream, fenebrutinib is “brain-penetrant.” It crosses the blood-brain barrier to inhibit B cells and microglia (immune cells in the brain) directly at the site of the damage.

The FENtrepid Trial: Breaking Down the Data

The Phase III FENtrepid study was a massive undertaking, enrolling 985 adults with PPMS. The trial compared daily oral fenebrutinib against Ocrevus infusions administered every six months.

The primary measure was the time to 12-week composite confirmed disability progression (cCDP12). This composite score is a rigorous “three-in-one” check that monitors:

1. Overall function (Expanded Disability Status Scale)

2. Walking speed (Timed 25-Foot Walk)

3. Manual dexterity (9-Hole Peg Test)

Key Findings:

• Reduced Risk: Fenebrutinib reduced the risk of disability progression by 12% compared to Ocrevus.

• Upper Limb Preservation: The drug showed a striking 26% reduction in the risk of worsening upper limb function.

• Early Impact: Benefits were measurable as early as week 24 and remained consistent throughout the 120-week study.

“Fenebrutinib showed a consistent clinical benefit as early as week 24, notably in upper limb function,” said Professor Amit Bar-Or, Director of the Center for Neuroinflammation at the University of Pennsylvania. “This is essential for preserving independence and daily functioning—the things that allow a patient to continue dressing, eating, and working.”

Expert Perspectives: Why “Oral” and “Brain-Penetrant” Matter

For patients, the move from a twice-yearly hospital infusion to a daily pill is more than just a matter of convenience; it’s about accessibility and consistent disease control.

Dr. Riley McCabe, a multiple sclerosis specialist at Johns Hopkins Medicine who was not involved in the trial, noted the significance of the drug’s mechanism. “The fact that this is a brain-penetrant therapy is the real story here. We are finally getting past the blood-brain barrier to target the ‘smoldering’ inflammation that drives PPMS,” Dr. McCabe explained. “While Ocrevus has been our only tool since 2017, an oral option could significantly improve treatment adherence.”

Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer, called the results the first potential scientific breakthrough for the PPMS community in over ten years.

Safety and Limitations

As with any high-efficacy therapy, fenebrutinib comes with side effects that require careful monitoring.

Side Effect Profile

Safety data was largely comparable between the oral drug and the infusion. The most common adverse events included:

• Infections: 67.0% for fenebrutinib vs. 70.9% for Ocrevus.

• Nausea: 12.0% for fenebrutinib vs. 7.1% for Ocrevus.

• Liver Enzymes: 13.3% of fenebrutinib patients saw a transient rise in liver enzymes, compared to 2.9% in the Ocrevus group. These elevations resolved after stopping the drug.

The Balanced View

While the results are historic, there are nuances to consider. Because the study was designed for “non-inferiority,” it proved that fenebrutinib is as good as Ocrevus, not necessarily better across the board.

Additionally, critics point to a slightly higher fatality rate in the fenebrutinib arm (1.4% vs 0.2%). However, investigators determined these deaths were unrelated to the drug and were consistent with the higher mortality rates generally seen in the MS population.

What’s Next for Patients?

Roche plans to submit these findings to global regulatory authorities, including the FDA and EMA, later this year. This timeline depends on the upcoming “readout” of another trial (FENhance 1) focused on the relapsing form of MS, expected in mid-2026.

For now, fenebrutinib is not yet available for prescription. Patients currently on Ocrevus or other therapies should not make any changes to their treatment plans based on these trial results.

“This is a moment of hope, but not a moment for immediate action,” says Dr. McCabe. “Patients should stay in close contact with their neurologists and monitor the regulatory progress of BTK inhibitors over the next 12 to 18 months.”

Practical Takeaways for the MS Community

• Independence: The data on upper-limb function suggests this drug may be particularly good at helping patients maintain the ability to perform daily tasks.

• Monitoring: If approved, patients using fenebrutinib will likely need regular blood tests to monitor liver health.

• Access: While a pill is easier to distribute than an infusion, the cost and global availability of new “breakthrough” therapies remain a hurdle for many patients in low-resource settings.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Roche. (2026, February 7). Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS). Press Release. https://www.roche.com/media/releases/med-cor-2026-02-07

• Reuters. (2026, February 7). Roche’s multiple sclerosis drug fenebrutinib meets goal in late-stage trial. https://www.reuters.com/business/healthcare-pharmaceuticals/roches-multiple-sclerosis-drug-fenebrutinib-meets-goal-late-stage-trial-2026-02-07/